Royalty Pharma Announces Inaugural Investor Day

Rhea-AI Summary

Royalty Pharma (Nasdaq: RPRX) has announced its inaugural Investor Day scheduled for May 17, 2022, in New York City, starting at 8:30 a.m. ET. Senior executives will discuss the future of royalty funding in life sciences, capital deployment opportunities, and long-term growth targets, featuring live Q&A sessions. Additional information will be provided closer to the event, with a live webcast available on the company’s Investors webpage. Royalty Pharma is known for its extensive portfolio, acquiring royalties on over 35 commercial products.

Positive

• Hosting inaugural Investor Day to discuss royalty funding and growth targets.
• Opportunity for investors to engage through live Q&A sessions.
• Strong portfolio with royalties on over 35 commercial products.

Negative

• None.

NEW YORK, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an inaugural Investor Day in New York City on Tuesday, May 17, 2022, starting at 8:30 a.m. ET. Royalty Pharma senior executives will present on the outlook for royalty funding in life sciences, the company’s capital deployment opportunities and long-term growth targets. The meeting will include live question and answer sessions.

Additional details will follow closer to the event. The live webcast may be accessed from the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events at the time of the meeting. A replay of the webcast will be archived on the Investors webpage for at least 30 days.

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Johnson & Johnsons’ Tremfya, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com 

FAQ

What is Royalty Pharma's upcoming Investor Day about?

Royalty Pharma's Investor Day, on May 17, 2022, will focus on the outlook for royalty funding, capital deployment options, and long-term growth targets.

When will Royalty Pharma's Investor Day take place?

The Investor Day is scheduled for May 17, 2022, starting at 8:30 a.m. ET.

How can I access the webcast for Royalty Pharma's Investor Day?

The webcast can be accessed from the Investors page on Royalty Pharma's website during the meeting.

What products does Royalty Pharma have royalties on?

Royalty Pharma's portfolio includes royalties on over 35 commercial products, such as AbbVie’s Imbruvica and Gilead’s Trodelvy.

Who will present at Royalty Pharma's Investor Day?

Senior executives of Royalty Pharma will present at the Investor Day.